Michelle Iacolina Selected Research

Therapeutics

1/2011	Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
4/2006	Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michelle Iacolina Research Topics

Disease

5	Neoplasms (Cancer) 01/2011 - 04/2006
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2011
1	Carcinogenesis 06/2007

Drug/Important Bio-Agent (IBA)

3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2011 - 06/2007
3	LigandsIBA 06/2009 - 01/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2011 - 06/2009
2	Growth Factor ReceptorsIBA 01/2011 - 01/2007
2	Platelet-Derived Growth FactorIBA 06/2007 - 01/2007
2	Bispecific AntibodiesIBA 01/2007 - 04/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2011
1	Sunitinib (Sutent)FDA Link 01/2011
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2011
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 06/2009
1	Proteins (Proteins, Gene)FDA Link 06/2009
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 06/2009
1	Angiogenesis InhibitorsIBA 06/2009
1	Becaplermin (PDGF-BB)FDA Link 06/2007
1	AntigensIBA 01/2007

Therapy/Procedure

2	Therapeutics 01/2011 - 04/2006